[Clinical observation of CD19-TANK cells in the treatment of relapsed/refractory B-cell lymphoma]

Zhonghua Xue Ye Xue Za Zhi. 2022 Feb 14;43(2):153-156. doi: 10.3760/cma.j.issn.0253-2727.2022.02.012.

[Article in Chinese]

Authors

X D Zhang¹, X R Fu¹, Z C Sun¹, L Zhang¹, X Li¹, L Li¹, J J Wu¹, X H Wang¹, F F Nan¹, Y Chang¹, H Yu¹, Z M Li¹, M Z Zhang¹

Affiliation

¹ Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.

PMID: 35381678
PMCID: PMC8980653
DOI: 10.3760/cma.j.issn.0253-2727.2022.02.012

No abstract available

MeSH terms

Antigens, CD19
Humans
Immunotherapy, Adoptive
Lymphoma, B-Cell* / therapy
Receptors, Chimeric Antigen*

Substances

Antigens, CD19
Receptors, Chimeric Antigen